Cornelius Taabazuing

Dr. Cornelius Taabazuing

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2019 in Science
Verified
Journal Article
Open access
PDF file
ACAshley J. Chui
Ashley J. Chui
MOMarian C. Okondo
Marian C. Okondo
SRSahana D. Rao
Sahana D. Rao
KGKuo Gai
Kuo Gai
AGAndrew R. Griswold
Andrew R. Griswold
DBDaniel A. Bachovchin
Daniel A. Bachovchin
Degradation triggers the alarm: Inflammasomes are multiprotein complexes that orchestrate proinflammatory cytokine secretion and cell death. Proteases such as anthrax lethal factor can activate an inflammasome known as NLRP1B, but the mechanism for this activation has been unclear. Chui et al. used genome-wide knockout screens to show that proteolysis of NLRP1B by lethal factor induces proteasomal degradation of the amino-terminal domains of NLRP1B and eventual cell death. Sandstrom et al. found that degradation of the amino-terminal domains of NLRP1B resulted in the release of a carboxyl-terminal fragment that activates caspase-1. This process, called “functional degradation,” allows the immune system to detect pathogen-associated activities, much as it recognizes pathogen-associated antigens. Science , this issue p. 82 , p. eaau1330

1 March 2012 in Cell
Verified
Journal Article
Closed access
JPJennifer S. Pfingsten
Jennifer S. Pfingsten
KGKaren J. Goodrich
Karen J. Goodrich
CTCornelius Taabazuing
Cornelius Taabazuing
FOFaissal Ouenzar
Faissal Ouenzar
PCPascal Chartrand
Pascal Chartrand
TCThomas R. Cech
Thomas R. Cech

15 December 2023 in Cell Reports
Verified
Journal Article
Open access
PEPatrick M. Exconde
Patrick M. Exconde
CHClaudia Hernandez-Chavez
Claudia Hernandez-Chavez
CBChristopher M. Bourne
Christopher M. Bourne
RRRachel M. Richards
Rachel M. Richards
MBMark B. Bray
Mark B. Bray
CTCornelius Taabazuing
Cornelius Taabazuing
Inflammasomes are multiprotein signaling complexes that activate the innate immune system. Canonical inflammasomes recruit and activate caspase-1, which then cleaves and activates IL-1β and IL-18, as well as gasdermin D (GSDMD) to induce pyroptosis. In contrast, non-canonical inflammasomes, caspases-4/-5 (CASP4/5) in humans and caspase-11 (CASP11) in mice, are known to cleave GSDMD, but their role in direct processing of other substrates besides GSDMD has remained unknown. Here, we show that CASP4/5 but not CASP11 can directly cleave and activate IL-18. However, CASP4/5/11 can all cleave IL-1β to generate a 27-kDa fragment that deactivates IL-1β signaling. Mechanistically, we demonstrate that the sequence identity of the tetrapeptide sequence adjacent to the caspase cleavage site regulates IL-18 and IL-1β recruitment and activation. Altogether, we have identified new substrates of the non-canonical inflammasomes and reveal key mechanistic details regulating inflammation that may aid in developing new therapeutics for immune-related disorders.

1 April 2014 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
CTCornelius Taabazuing
Cornelius Taabazuing
JHJohn A. Hangasky
John A. Hangasky
MKMichael J. Knapp
Michael J. Knapp

1 August 2012 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
SFShannon C. Flagg
Shannon C. Flagg
CMCristina B. Martin
Cristina B. Martin
CTCornelius Taabazuing
Cornelius Taabazuing
BHBreanne E. Holmes
Breanne E. Holmes
MKMichael J. Knapp
Michael J. Knapp

16 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
CBCHRISTOPHER BOURNE
CHRISTOPHER BOURNE
CTCornelius Taabazuing
Cornelius Taabazuing
Cancer immunotherapy is a novel pillar of cancer treatment that harnesses the immune system to fight tumors and generally results in robust antitumor immunity. Although immunotherapy has achieved remarkable clinical success for some patients, many patients do not respond, underscoring the need to develop new strategies to promote antitumor immunity. Pyroptosis is an immunostimulatory type of regulated cell death that activates the innate immune system. A hallmark of pyroptosis is the release of intracellular contents such as cytokines, alarmins, and chemokines that can stimulate adaptive immune activation. Recent studies suggest that pyroptosis promotes antitumor immunity. Here, we review the mechanisms by which pyroptosis can be induced and highlight new strategies to induce pyroptosis in cancer cells for antitumor defense. We discuss how pyroptosis modulates the tumor microenvironment to stimulate adaptive immunity and promote antitumor immunity. We also suggest research areas to focus on for continued development of pyroptosis as an anticancer treatment. Pyroptosis-based anticancer therapies offer a promising new avenue for treating immunologically ‘cold’ tumors.